|
|
|
Volumn 26, Issue 5 SUPPL. 17, 1999, Pages 19-23
|
|
A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BICALUTAMIDE;
DEXAMETHASONE;
DIPHENHYDRAMINE;
DOCETAXEL;
DOXORUBICIN;
ESTRAMUSTINE;
ETOPOSIDE;
FLUTAMIDE;
KETOCONAZOLE;
MITOXANTRONE;
PACLITAXEL;
PROSTATE SPECIFIC ANTIGEN;
PROTEIN BCL 2;
RANITIDINE;
VINBLASTINE;
ADULT;
AGED;
ANEMIA;
ANTINEOPLASTIC ACTIVITY;
CANCER HORMONE THERAPY;
CANCER RESISTANCE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG HYPERSENSITIVITY;
FEVER;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
MALE;
MUCOSA INFLAMMATION;
NAUSEA;
NEUTROPENIA;
ORAL DRUG ADMINISTRATION;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CANCER;
PROTEIN PHOSPHORYLATION;
REVIEW;
THROMBOCYTOPENIA;
VOMITING;
AGED;
ANTINEOPLASTIC AGENTS, HORMONAL;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
GENE EXPRESSION;
HUMANS;
MALE;
MIDDLE AGED;
NEOPLASMS, HORMONE-DEPENDENT;
PACLITAXEL;
PHOSPHORYLATION;
PROSTATIC NEOPLASMS;
PROTO-ONCOGENE PROTEINS C-BCL-2;
TAXOIDS;
|
|
EID: 0033406349
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (151)
|
|
References (14)
|
